As Second Vice President, Olivier Laureau will continue to defend the pharmaceutical sector, bringing in Servier’s values as well as defending the interests of the EFPIA European Mid-Size Pharmaceutical Companies.
He will be working together with the President (Hubertus Von Baumbach from Boehringer Ingelheim) and the first Vice-President (Lars Fruergaard Jørgensen from Novo Nordisk) leading the work of the federation for a two-year mandate.
“Recent events have demonstrated the key role medical innovation plays in keeping our society safe and healthy” said Olivier Laureau. “Our ambition is for Europe to be a world leader in life science. Realising that goal means EFPIA and its membership working with the EU and Member States to build a world-class regulatory system, a strong and predictable IP framework and a next generation life sciences eco-system that delivers for patients across Europe and around the world.”
Servier is a member of EFPIA since 1997.
Read EFPIA’s press release: zveze EFPIA